Clinical Trial for Registration of HPV Nucleic Acid Genotyping Assay Kit

NACompletedINTERVENTIONAL
Enrollment

12,230

Participants

Timeline

Start Date

August 23, 2020

Primary Completion Date

August 26, 2024

Study Completion Date

August 26, 2024

Conditions
Cervical Cancer
Interventions
DIAGNOSTIC_TEST

HPV Genotyping Nucleic Acid Assay Kit

The total sample size of screening population is approximately 12,000 cases (all females ≥ 21 years of age). Two cervical cytology samples will be collected from each subject with a tube of SurePath sample followed by a tube of PreservCyt sample. The 1st tube of SurePath liquid-based cytology sample is used for cytology test and BD Onclarity Assay HPV detection. Subjects with cytology test results ≥ ASCUS or positive HPV test results will be suggested to return for baseline colposcopy within approximately 12 weeks.

Trial Locations (5)

Unknown

Cancer Hospital Chinese Academy of Medical Science, Beijing

Henan Cancer Hospital, Zhengzhou

Obstetrics&Gynecology Hospital of Fudan University, Shanghai

Heping Hospital Affilated to Changzhi Medical College, Changzhi

Women's Hospital School of Medicine Zhejiang University, Hangzhou

Sponsors
All Listed Sponsors
lead

Becton, Dickinson and Company

INDUSTRY